Chardan Capital Issues Optimistic Forecast for OBIO Earnings

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Equities researchers at Chardan Capital lifted their FY2025 EPS estimates for Orchestra BioMed in a report released on Wednesday, April 2nd. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings of ($1.88) per share for the year, up from their prior estimate of ($1.99). Chardan Capital currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.66) per share.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright lowered their target price on Orchestra BioMed from $14.00 to $12.00 and set a “buy” rating for the company in a report on Friday, April 4th. BTIG Research started coverage on shares of Orchestra BioMed in a research note on Thursday, March 20th. They issued a “buy” rating and a $12.00 price objective for the company. B. Riley raised shares of Orchestra BioMed to a “strong-buy” rating in a research report on Thursday, April 3rd. Finally, Barclays began coverage on shares of Orchestra BioMed in a research report on Thursday, January 2nd. They issued an “overweight” rating and a $16.00 price target for the company. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Orchestra BioMed presently has a consensus rating of “Buy” and an average target price of $15.00.

Orchestra BioMed Stock Down 1.4 %

Shares of NASDAQ:OBIO opened at $2.79 on Monday. The business’s 50 day moving average is $4.55 and its 200 day moving average is $5.06. The stock has a market cap of $106.06 million, a P/E ratio of -1.73 and a beta of 0.62. Orchestra BioMed has a 52-week low of $2.49 and a 52-week high of $8.87.

Orchestra BioMed (NASDAQ:OBIO) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.43). The company had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.79 million. Orchestra BioMed had a negative net margin of 2,179.33% and a negative return on equity of 107.04%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its holdings in Orchestra BioMed by 3.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 217,008 shares of the company’s stock worth $1,115,000 after purchasing an additional 8,107 shares during the last quarter. State Street Corp grew its stake in Orchestra BioMed by 12.4% during the 3rd quarter. State Street Corp now owns 429,613 shares of the company’s stock worth $2,208,000 after buying an additional 47,308 shares during the last quarter. Barclays PLC increased its position in Orchestra BioMed by 281.3% during the 3rd quarter. Barclays PLC now owns 31,785 shares of the company’s stock valued at $163,000 after buying an additional 23,448 shares in the last quarter. Geode Capital Management LLC raised its stake in Orchestra BioMed by 2.0% in the third quarter. Geode Capital Management LLC now owns 567,219 shares of the company’s stock valued at $2,916,000 after buying an additional 11,002 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Orchestra BioMed by 26.0% in the fourth quarter. SG Americas Securities LLC now owns 12,785 shares of the company’s stock worth $51,000 after acquiring an additional 2,642 shares in the last quarter. Hedge funds and other institutional investors own 53.55% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.